Macrocyclic peptidyl hydroxamates were designed as peptide deformylase inhibitors, showing potent enzyme inhibition for this bacteria-selective antibiotic target — advancing macrocyclic antibiotic drug design.
Key findingMacrocyclic peptidyl hydroxamate peptide deformylase inhibitors showed potent enzyme inhibition, with the macrocyclic constraint and hydroxamate metal
What the researchers found
Macrocyclic peptidyl hydroxamate peptide deformylase inhibitors showed potent enzyme inhibition, with the macrocyclic constraint and hydroxamate metal chelation providing dual binding optimization for this bacteria-selective antibiotic target.
Why it matters
Relevant for cyclic-peptides, antimicrobial-peptides, peptide-design.
How the study worked
in-vitro study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Design and synthesis of macrocyclic peptidyl hydroxamates as peptide deformylase inhibitors.
Bioorganic & medicinal chemistry letters, 18(10), 3060-3
Citation
Shen, Gang; Zhu, Jinge; Simpson, Anthony M; Pei, Dehua. (2008). Design and synthesis of macrocyclic peptidyl hydroxamates as peptide deformylase inhibitors.. Bioorganic & medicinal chemistry letters, 18(10), 3060-3.